Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2005;36:1059-1064
Published online before print April 7, 2005, doi: 10.1161/01.STR.0000163050.39122.4f
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
36/5/1059    most recent
01.STR.0000163050.39122.4fv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benchenane, K.
Right arrow Articles by Ali, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benchenane, K.
Right arrow Articles by Ali, C.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*GLUCOSE
Related Collections
Right arrow Cell biology/structural biology
Right arrow Ischemic biology - basic studies
Right arrow Fibrinolysis
Right arrow Thrombolysis
Right arrow Other Vascular biology

(Stroke. 2005;36:1059.)
© 2005 American Heart Association, Inc.


Original Contributions

Oxygen Glucose Deprivation Switches the Transport of tPA Across the Blood–Brain Barrier From an LRP-Dependent to an Increased LRP-Independent Process

Karim Benchenane, PhD; Vincent Berezowski, PhD; Mónica Fernández-Monreal, PhD; Julien Brillault, PhD; Samuel Valable, PhD; Marie-Pierre Dehouck, PhD; Roméo Cecchelli, PhD; Denis Vivien, PhD; Omar Touzani, PhD Carine Ali, PhD

From INSERM-Avenir (K.B., D.V., C.A.), Centre Cyceron, Université de Caen, France; CNRS UMR 6185 (K.B., M.F.-M., S.V., O.T.), Université de Caen, Centre Cyceron, France; Laboratoire de Physiopathologie de la Barrière Hémato-Encéphalique (V.B., J.B., M.-P.D., R.C.), EA 2465, Université d’Artois, Faculté des sciences Jean Perrin, France; and the Department of Pharmacology (M.F.-M. current affiliation), State University of New York, Stony Brook, NY.

Correspondence to Prof Denis Vivien, INSERM-Avenir, Centre Cyceron, Université de Caen, Boulevard Becquerel, 14074 Caen Cedex, France. E-mail d.vivien{at}neuro.unicaen.fr

Background and Purpose— Despite uncontroversial benefit from its thrombolytic activity, the documented neurotoxic effect of tissue plasminogen activator (tPA) raises an important issue: the current emergency stroke treatment might not be optimum if exogenous tPA can enter the brain and thus add to the deleterious effects of endogenous tPA within the cerebral parenchyma. Here, we aimed at determining whether vascular tPA crosses the blood–brain barrier (BBB) during cerebral ischemia, and if so, by which mechanism.

Methods— First, BBB permeability was assessed in vivo by measuring Evans Blue extravasation following intravenous injection at 0 or 3 hours after middle cerebral artery electrocoagulation in mice. Second, the passage of vascular tPA was investigated in an in vitro model of BBB, subjected or not to oxygen and glucose deprivation (OGD).

Results— We first demonstrated that after focal permanent ischemia in mice, the BBB remains impermeable to Evans Blue in the early phase (relative to the therapeutic window of tPA), whereas at later time points massive Evans Blue extravasation occurs. Then, the passage of tPA during these 2 phases, was investigated in vitro and we show that in control conditions, tPA crosses the intact BBB by a low-density lipoprotein (LDL) receptor-related protein (LRP)-dependent transcytosis, whereas OGD leads to an exacerbation of tPA passage, which switches to a LRP-independent process.

Conclusion— We evidence 2 different mechanisms through which vascular tPA can reach the brain parenchyma, depending on the state of the BBB. As discussed, these data show the importance of taking the side effects of blood-derived tPA into account and offer a basis to improve the current thrombolytic strategy.


Key Words: blood–brain barrier • stroke • thrombolytic therapy • tissue plasminogen activator




This article has been cited by other articles:


Home page
HypertensionHome page
C. Vecchione, A. Frati, A. Di Pardo, G. Cifelli, D. Carnevale, M. T. Gentile, R. Carangi, A. Landolfi, P. Carullo, U. Bettarini, et al.
Tumor Necrosis Factor-{alpha} Mediates Hemolysis-Induced Vasoconstriction and the Cerebral Vasospasm Evoked by Subarachnoid Hemorrhage
Hypertension, July 1, 2009; 54(1): 150 - 156.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. T. Zia, A. Csiszar, N. Labinskyy, F. Hu, G. Vinukonda, E. F. LaGamma, Z. Ungvari, and P. Ballabh
Oxidative-Nitrosative Stress in a Rabbit Pup Model of Germinal Matrix Hemorrhage: Role of NAD(P)H Oxidase
Stroke, June 1, 2009; 40(6): 2191 - 2198.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. A. Miller, G. R. Drummond, T. M. De Silva, A. E. Mast, H. Hickey, J. P. Williams, B. R. S. Broughton, and C. G. Sobey
NADPH oxidase activity is higher in cerebral versus systemic arteries of four animal species: role of Nox2
Am J Physiol Heart Circ Physiol, January 1, 2009; 296(1): H220 - H225.
[Abstract] [Full Text] [PDF]